A pharmaceutical giant wants to talk to decision-makers at Queen's Park.
Janssen Inc. was registered to lobby this past week by its president Laetitia Decroix Guilloux.
The focus of their discussions with officials centered around current and emerging policies impacting the evaluation, marketing, sale or use of pharmaceutical products in Ontario, such as the Pan-Canadian Pharmaceutical Alliance, national pharmacare, subsequent-entry biologics, regulation changes to the Patented Medicines Product Review Board and the use of real-world evidence in the evaluation of pharmaceutical products. The goal of their lobbying efforts is to support the development of a strong life science strategy.
